MetaCap

Delcath Systems (DCTH) vs vVARDIS (VVVV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

vVARDIS is the larger company by market cap ($770.9 million vs $653.7 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DCTH-8.56%VVVV-11.82%
+1%-6%-12%
Nov 13, 20261 yearNov 20, 2026
DCTH-8.56%VVVV-11.82%
+1%-6%-12%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DCTH versus VVVV key metrics
MetricDCTHVVVV
Share price$18.79$14.55
Market cap$653.67M$770.91M
1-day change-2.34%-3.00%
YTD return+86.04%—
1-year return+109.71%—
5-year return+92.92%—
P/E ratio (TTM)117.44—
Forward P/E68.95—
EPS (TTM)$0.16$-0.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$85.23M—
Revenue growth (YoY)+129.08%—
Net income (latest FY)$2.70M—
Gross margin86.16%—
Operating margin0.77%—
Net margin3.17%—
52-week high$22.51$16.95
52-week low$8.49$14.00
Distance from 52-week high-16.53%-14.16%
Analyst consensusstrong_buy—
Avg. price target upside+52.21%—
Average volume497.48K963.08K
Shares outstanding34.79M38.59M
Employees156153
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Delcath Systems

DCTH stock →

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Health Care · Medical/Dental Instruments · 156 employees

About vVARDIS

VVVV stock →

vVARDIS Holding AG, a dental medtech company, develops and provides non-invasive cavity treatment products in Switzerland and the United States. The company offers the Curodont platform, including Curodont Repair, a biomimetic system to arrest and reverse early caries through enamel regeneration; Curodont Protect, a remineralising tooth gel containing the biomimetic Oligo-Peptide 103 technology; and Enamel Serum, enriched with peptides and hydroxyapatite, which delivers calcium and phosphate ions to care for the enamel.

Health Care · Medical/Dental Instruments · 153 employees

DCTH vs VVVV FAQ

Which is bigger, Delcath Systems or vVARDIS?

vVARDIS (VVVV) is larger, with a market capitalization of $770.91M compared with $653.67M for Delcath Systems (DCTH).

Are Delcath Systems and vVARDIS in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons